Anticancer potential of fused heterocycles: structural insights and mechanistic advances.

IF 0.9 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Asian Biomedicine Pub Date : 2025-12-31 eCollection Date: 2025-12-01 DOI:10.2478/abm-2025-0035

Aaysha Pandey, Shubham Sharma, Kamal Kishore, Swati Rani, Man Vir Singh, Gangotri Pemawat

引用次数: 0

Abstract

β-lactam derivatives, carbazoles, isatin derivatives, pyrrolo-benzodiazepines (PBDs), and pyrido[2,3-d]pyrimidines have demonstrated potential as anticancer agents among organic compounds. They exhibit substantial anticancer efficacy across several cancer cell lines, such as HL-60, THP-1, U-937, HeLa, PANC1, MDA-MB-231, and A549 cell lines. These compounds display a significant anticancer profile via diverse biological pathways such as DNA interaction, kinase inhibition, microtubule disruption, and enzyme inhibition. Their low IC50 values across various cell lines suggest their viability as strong candidates for targeted and multi-mechanistic cancer therapy, warranting further in vivo and clinical exploration. This review thoroughly summarized the anticancer efficacy of β-lactam derivatives, carbazoles, isatins, PBDs, and pyrido[2,3-d]pyrimidine derivatives.

查看原文本刊更多论文

融合杂环化合物的抗癌潜力：结构见解和机制进展。

在有机化合物中，β-内酰胺衍生物、咔唑、isatin衍生物、吡咯-苯二氮卓类（PBDs）和吡啶[2,3-d]嘧啶已被证明是潜在的抗癌剂。它们在多种癌细胞系（如HL-60、THP-1、U-937、HeLa、PANC1、MDA-MB-231和A549细胞系）中表现出显著的抗癌功效。这些化合物通过多种生物学途径，如DNA相互作用、激酶抑制、微管破坏和酶抑制，显示出显著的抗癌特征。它们在各种细胞系中的IC50值较低，这表明它们作为靶向和多机制癌症治疗的强有力候选者，值得进一步的体内和临床探索。本文综述了β-内酰胺类衍生物、咔唑类、isatins类、PBDs类和吡啶类[2,3-d]嘧啶类衍生物的抗癌作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Biomedicine 医学-医学：研究与实验

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Asian Biomedicine: Research, Reviews and News (ISSN 1905-7415 print; 1875-855X online) is published in one volume (of 6 bimonthly issues) a year since 2007. [...]Asian Biomedicine is an international, general medical and biomedical journal that aims to publish original peer-reviewed contributions dealing with various topics in the biomedical and health sciences from basic experimental to clinical aspects. The work and authorship must be strongly affiliated with a country in Asia, or with specific importance and relevance to the Asian region. The Journal will publish reviews, original experimental studies, observational studies, technical and clinical (case) reports, practice guidelines, historical perspectives of Asian biomedicine, clinicopathological conferences, and commentaries Asian biomedicine is intended for a broad and international audience, primarily those in the health professions including researchers, physician practitioners, basic medical scientists, dentists, educators, administrators, those in the assistive professions, such as nurses, and the many types of allied health professionals in research and health care delivery systems including those in training.